Clinical Trial Update: Octreotide Efficacy and Safety in First-line Acromegalic Patients [Phase 4]

View source ↗

Summary

Phase 4 trial results evaluate octreotide as first-line therapy for acromegaly, reporting its efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Sandostatin (Octreotide acetate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Phase 4 | Status: COMPLETED